0000950170-24-129402 Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 20th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2024, between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON SHARE PURCHASE WARRANT Lineage Cell Therapeutics, Inc.Common Share Purchase Warrant • November 20th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 21, 2025 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) the three (3) year anniversary of the Initial Exercise Date, and (ii) the 90th day following the date of the public disclosure of the occurrence of the Milestone Event subject to the satisfaction of the Equity Conditions (as defined below), or if the date of the public disclosure of the occurrence of the Milestone Event occurs prior to the Initial Exercise Date, the 90th day following the Initial Exercise Date, subject to the satisfaction of the Equity Conditions (the “Termination Date”), but not thereafter, to subscribe for and purchase from Lineage Cell Therapeutics, Inc., a California corporation (the “Comp
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 20th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2024, between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT Lineage Cell Therapeutics, Inc.Placement Agent Common Share Purchase Warrant • November 20th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 21, 2025 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) the three (3) year anniversary of the Initial Exercise Date, and (ii) the 90th day following the date of the public disclosure of the occurrence of the Milestone Event subject to the satisfaction of the Equity Conditions (as defined below), or if the date of the public disclosure of the occurrence of the Milestone Event occurs prior to the Initial Exercise Date, the 90th day following the Initial Exercise Date, subject to the satisfaction of the Equity Conditions (the “Termination Date”), but not thereafter, to subscribe for and purchase from Lineage Cell Therapeutics, Inc., a California corpor